Oral Ferroportin Inhibitor
-
Product Information
Scientific name: Vamifeport (VIT-2763)
Brand name: N/A
RESPONSIBLE: CSL -
Clinical Trial/Study Information
Trial Name: ViSion Serenity
Code: NCT04817670
Phase: 2a
Eligible patient diagnosis: Adults with sickle cell disease (SCD) (sickle haemoglobin (HbS)/S or HbS/βT0 genotype)
No. of Patients enrolled: 24 (Last update: 16/4/2024)
Study Sites: 22 Sites per countryCompletion date: 7 March 2024
Scope of the Study / Aim: Explore the effect of VIT-2763 on markers of haemolysis / assess the safety and tolerability of VIT-2763 in SCD patients. -
Regulatory Information
Status: Not Authorised
Additional notable points:
- EMA: Orphan drug designation (2021)
- FDA: Orphan drug designation (2021)
- MHRA: N/A
Update: 19 December 2024
No update available.
Update: 30 September 2024
No update available.
Update: 30 June 2024
No update available.
Update: 31 March 2024
All expected patients have been enrolled (total: 24 patients) and the last patient visit occurred on 7th March 2024.
Source: Company correspondence
Update: 20 December 2023
18 patients enrolled so far (7/11/2023). Last patient to be enrolled expected on 22/12/2023.
Source: Company correspondence
Update: 30 September 2023
No update available.
Update: 30 June 2023
No update available.
Update: 31 March 2023
No update available.
